LIT-1 Inhibitors
Chemical inhibitors of LIT-1 can achieve functional inhibition through various mechanisms by targeting different signaling pathways and kinases that interact with or regulate LIT-1 activity. Staurosporine, a potent protein kinase inhibitor, directly inhibits the kinase activity of LIT-1, preventing phosphorylation events that would ordinarily be catalyzed by LIT-1. In a similar manner, dasatinib, a broad-spectrum tyrosine kinase inhibitor, can obstruct LIT-1's kinase activity if LIT-1 exhibits or is influenced by tyrosine kinase-like functions. Additionally, sorafenib, as a multikinase inhibitor targeting RAF kinases, could indirectly diminish LIT-1 activity if LIT-1 operates within the RAF-influenced pathways.
Moreover, several inhibitors disrupt upstream components of signaling cascades influencing LIT-1 function. LY294002 and wortmannin, both PI3K inhibitors, could curtail PI3K/Akt signaling, therefore indirectly reducing LIT-1 activity if it is downstream of this pathway. Rapamycin, an mTOR inhibitor, operates within the same PI3K/AKT/mTOR pathway and can have similar suppressive effects on LIT-1. MAPK pathway inhibitors, such as SP600125, SB203580, PD98059, and U0126, disrupt the kinase cascades that potentially regulate LIT-1. SP600125 inhibits JNK, while SB203580 specifically inhibits p38 MAP kinase, and both PD98059 and U0126 prevent MEK from activating ERK1/2. The effect of these inhibitors could cascade down to LIT-1, reducing its activity due to the inhibition of upstream signaling molecules. Lastly, PP2, by inhibiting Src family kinases, and PD173074, by inhibiting FGFR1 and VEGFR2, can attenuate the functional state of LIT-1 if it is regulated by Src-related signals or lies downstream of FGF signaling, respectively. Through these diverse but specific mechanisms, each chemical can result in the inhibition of LIT-1's kinase function by disrupting the signaling pathways that govern its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, and since LIT-1 is a kinase, it would inhibit its kinase activity directly, preventing phosphorylation of downstream targets. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which participates in the MAPK signaling pathway. By inhibiting JNK, SP600125 may reduce the phosphorylation and activity of LIT-1, which is known to be regulated by the MAPK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. Inhibition of p38 MAP kinase could lead to decreased activation of LIT-1, which is potentially regulated by MAPK signaling cascades. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of PI3K, which is part of the PI3K/Akt signaling pathway. PI3K influences various kinases, and inhibiting it could indirectly inhibit LIT-1 activity if LIT-1 is downstream of PI3K/Akt signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, which acts upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 would prevent the activation of ERK and potentially other kinases, such as LIT-1, that are regulated by the MAPK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of ERK1/2. As LIT-1 is potentially regulated by the MAPK pathway, inhibiting MEK could indirectly inhibit LIT-1 kinase activity by blocking upstream signals. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a key protein in the PI3K/AKT/mTOR pathway, and could indirectly inhibit LIT-1 if LIT-1 is acting downstream or is modulated by mTOR signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor like LY294002, and it would similarly inhibit the PI3K/Akt pathway, potentially reducing the activity of downstream kinases such as LIT-1. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor, and while LIT-1 is not a member of this family, if LIT-1's activity is contingent upon Src signaling, PP2 could indirectly inhibit its function. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 is an inhibitor of the FGFR1 and VEGFR2. If LIT-1 is influenced by FGF signaling mediated through FGFR1, this inhibitor could indirectly reduce LIT-1 kinase activity. | ||||||